Key facts
- Notable investors include Sinopharm Group, Tenyall Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Jinju Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Jinju Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jinju Biomedicine
Manufacturer of a cell-therapy biopharmaceutical products company intended to develop stem-cell spheroid therapies. The company offers a stem cell sphere treatment, injectable stem-cell products, and multiple therapeutic-area coverage (joints, heart, anti-aging, etc.), enabling clinical and medical-cosmetic developers to access advanced regenerative therapies.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Jinju Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jinju Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jinju Biomedicine in its N-PORT filings yet. We sweep new filings monthly.